Senores Pharmaceuticals Q1 FY27: Revenue up 36% to ₹180 Cr, PAT up 56% to ₹31 Cr
Senores Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹180.21 crore, up 36% YoY. PAT grew 56% to ₹30.45 crore. Regulated Markets revenue surged 42%, and Emerging Markets grew 30%. EBITDA increased 87% with margin expansion. Ms. Anjali Shah was appointed Senior Management Personnel.
The substantial increase in revenue and profit, coupled with strategic growth in key markets and product portfolio expansion, indicates a significant positive impact on the company's financial health and market position.
The company reported strong year-on-year growth in revenue and profits, along with significant margin expansion and strategic portfolio growth. The appointment of a new SMP also indicates proactive management.
Senores Pharmaceuticals Limited announced its unaudited financial results for the quarter ended June 30, 2026, reporting a robust performance across consolidated and standalone segments. The company's total revenue for Q1 FY27 increased by 36% year-on-year to ₹180.21 crore, compared to ₹132.56 crore in the same period last year. Profit After Tax (PAT) saw a significant jump of 56% to ₹30.45 crore from ₹19.48 crore in Q1 FY26.
The Board of Directors, in their meeting held on July 27, 2026, approved these unaudited financial results. The meeting commenced at 1:45 PM IST and concluded at 2:55 PM IST.
Key drivers for the revenue growth included a 41.9% increase in revenue from Regulated Markets to ₹127.8 crore and a 29.6% rise in Emerging Markets to ₹37.6 crore. EBITDA for the quarter grew by 87% year-on-year, with EBITDA margins expanding by approximately 800 basis points. The company highlighted the expansion of its product portfolio, with the number of approved ANDAs increasing from 30 in June 2025 to 58 in June 2026.
In addition to the financial results, the Board also approved the appointment of Ms. Anjali Shah as Senior Management Personnel (SMP), effective July 27, 2026. Ms. Shah, an Assistant Vice President - Finance, is a qualified Chartered Accountant with over 10 years of experience in finance, taxation, and financial reporting.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.